Skin atrophy caused by topical glucocorticoids is less common in patients with atopic dermatitis than in those with psoriasis

2021 ◽  
Author(s):  
Chung Hyeok Lee ◽  
Sung Jay Choe ◽  
Dong Hye Kim ◽  
Eun Jung Kim ◽  
Minseob Eom ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Skin Atrophy ◽  
Topical Glucocorticoids

scholarly journals 099 Skin atrophy due to topical glucocorticoids is less common in patients with atopic dermatitis than psoriasis

2019 ◽  
Vol 139 (9) ◽  
pp. S231
Author(s):  
C. Lee ◽  
S. Choe ◽  
D. Kim ◽  
E. Kim ◽  
S. Hong ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Skin Atrophy ◽  
Topical Glucocorticoids

Knemometry in children with atopic dermatitis treated with topical glucocorticoids.

1998 ◽  
Vol 15 (1) ◽  
pp. 7-11 ◽  
Author(s):  
C Heuck ◽  
T Ternowitz ◽  
T Herlin ◽  
OD Wolthers
Keyword(s):  
Atopic Dermatitis ◽  
Topical Glucocorticoids

scholarly journals Topical Tacrolimus for Psoriasis

2009 ◽  
Vol 2 (1) ◽  
pp. 51-55 ◽  
Author(s):  
Toshiyuki Yamamoto
Keyword(s):  
Atopic Dermatitis ◽  
Recent Progress ◽  
Therapeutic Strategies ◽  
Skin Atrophy ◽  
Topical Tacrolimus ◽  
Beneficial Effects ◽  
First Choice ◽  
Short Period ◽  
Tacrolimus Therapy ◽  
Genital Psoriasis

Tacrolimus ointment is an agent approved for the treatment of atopic dermatitis; however, tacrolimus has been expected also as one of the promising therapeutic strategies for other T-cell mediated inflammatory skin disorders. Recent progress have demonstrated that topical tacrolimus shows beneficial effects for psoriasis depending on sites. In particular, facial, intertriginous, and genital psoriasis respond to topical tacrolimus dramatically in a short period. Further, topical tacrolimus is tolerable also for child psoriasis. Because topical tacrolimus does not induce either skin atrophy or telangiectasia different from corticosteroids, it is recommended to be a first choice. The most proper way of topical tacrolimus therapy at present is to use this ointment intermittently after the remission was once obtained, paying attention to its adverse effects.

Prednicarbate (Dermatop®): Profile of a Corticosteroid

2004 ◽  
Vol 8 (4) ◽  
pp. 244-247 ◽  
Author(s):  
Aditya K. Gupta ◽  
Melody Chow
Keyword(s):  
Atopic Dermatitis ◽  
Adverse Events ◽  
Elderly Patients ◽  
Topical Steroid ◽  
Topical Steroids ◽  
Skin Atrophy ◽  
Intermittent Treatment ◽  
Alternative Agent ◽  
Inflammatory Action

Background: Topical steroids have been a popular choice for treating various cutaneous disorders; however, the potential for significant local and systemic adverse events, like skin atrophy and hypothalamic–pituitary–adrenal (HPA) axis suppression, has limited their use. Objective: This article reviews the topical steroid prednicarbate through its mechanism of action, clinical efficacy, and adverse events profile. Methods: Published literature containing the word “prednicarbate” was examined and summarized. Results: Prednicarbate is a nonhalogenated, double-ester derivative of prednisolone that has been used in the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as atopic dermatitis. It has a favorable benefit–risk ratio, low skin atrophy potential, and high anti-inflammatory action. Conclusion: These characteristics make prednicarbate an ideal alternative agent for children, elderly patients, and those who require long-term intermittent treatment.

Knemometry in Children with Atopic Dermatitis Treated with Topical Glucocorticoids

2009 ◽  
Vol 15 (1) ◽  
pp. 7-11
Author(s):  
Carsten Heuck ◽  
Thomas Ternowitz ◽  
Troels Herlin ◽  
Ole D. Wolthers
Keyword(s):  
Atopic Dermatitis ◽  
Topical Glucocorticoids

scholarly journals Vulvar Skin Atrophy Induced by Topical Glucocorticoids

2012 ◽  
Vol 57 (3) ◽  
pp. 296-299 ◽  
Author(s):  
Elisabeth Johnson ◽  
Pamela Groben ◽  
Alisa Eanes ◽  
Priya Iyer ◽  
Joseph Ugoeke ◽  
...  
Keyword(s):  
Skin Atrophy ◽  
Topical Glucocorticoids
Sign in / Sign up

Export Citation Format

Share Document